EMA And HMA Speak Out In Favor Of Biosimilar Interchangeability

All Biosimilars Can Be Substituted In EU With Member States’ Consent

 
• By Chloe Kent
  
Generate a summary of this article
Listen to this article
Beta

Stakeholders in Europe have been hesitant to allow interchangeable substitution of biological products, prompting the European Medicines Agency to clarify its stance on the issue.

Pharmacist speaking to patient at counter
Biosimilar interchangeability has a notably different meaning in the US compared to the EU • Source: Shutterstock

The European Medicines Agency and Heads of Medicines’ Agencies Biosimilars Working Group has issued a statement highlighting its support for biosimilar interchangeability. The agencies have emphasized that biosimilars the EMA has approved are all interchangeable as a clinical matter and can be substituted for branded biologics wherever national regulatory agencies allow it.

Joint EMA/HMA Statement On Interchangeability

  • Interchangeability refers to the possibility of exchanging one medicine for another medicine that is expected to have the same clinical effect.

“Considering all the available scientific evidence and the successful experience with biosimilars in clinical practice over the years, the Committee...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

GB-ProductsBiosimilars-Free-Commentary-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

GB-Premium-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Products

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Has An Ally In Argentina On Infliximab

Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.